ALZAMIN Trademark

Trademark Overview

On Wednesday, September 16, 2020, a trademark application was filed for ALZAMIN with the United States Patent and Trademark Office. The USPTO has given the ALZAMIN trademark a serial number of 90184905. The federal status of this trademark filing is REGISTERED as of Tuesday, July 13, 2021. This trademark is owned by GRIFOLS, S.A.. The ALZAMIN trademark is filed in the Pharmaceutical Products category with the following description:

Blood derivatives, namely, albumin for medical use
alzamin

General Information

Serial Number90184905
Word MarkALZAMIN
Filing DateWednesday, September 16, 2020
Status700 - REGISTERED
Status DateTuesday, July 13, 2021
Registration Number6415219
Registration DateTuesday, July 13, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 16, 2021

Trademark Statements

Goods and ServicesBlood derivatives, namely, albumin for medical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 26, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGRIFOLS, S.A.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBarcelona 08022
ES
Party NameGRIFOLS, S.A.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBarcelona 08022
ES
Party NameGRIFOLS, S.A.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBarcelona 08022
ES

Trademark Events

Event DateEvent Description
Saturday, September 19, 2020NEW APPLICATION ENTERED
Monday, October 26, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 29, 2021ASSIGNED TO EXAMINER
Tuesday, February 2, 2021EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Tuesday, February 2, 2021COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Tuesday, February 2, 2021EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Tuesday, February 2, 2021NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Thursday, February 4, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 4, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 4, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 16, 2021PUBLISHED FOR OPPOSITION
Tuesday, March 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 11, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 25, 2021TEAS DELETE 1(B) BASIS RECEIVED
Thursday, June 10, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, May 25, 2021NOTICE OF ALLOWANCE CANCELLED
Thursday, June 10, 20211(B) BASIS DELETED; PROCEED TO REGISTRATION
Tuesday, July 13, 2021REGISTERED-PRINCIPAL REGISTER
Monday, July 13, 2026COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

alzamin medical albumin namely derivatives blood